HAVRIX
STN: BL 103475
Proper Name: Hepatitis A Vaccine
Tradename: HAVRIX
Manufacturer: GlaxoSmithKline Biologicals
Indication:
- HAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV).
- HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.
Product Information
Supporting Documents
- October 27, 2023 Approval Letter - HAVRIX
- December 3, 2021 Approval Letter - HAVRIX
- December 19, 2018 Approval Letter - HAVRIX
- Supporting Documents older than three years - HAVRIX